Skip to content
Baltimore News Journal – Lifestyle
Author:
Lir Life Sciences Corp.
LIR Life Sciences Announces Initiation of Phase 1 Macromolecule-Enabled Transdermal Delivery Development with Neuland Laboratories
May 22, 2026
LIR Life Sciences Launches Ex Vivo Animal Study to Evaluate Protamine Enhanced Transdermal Transport of Larger Format Therapeutic Molecules
April 28, 2026
LIR Life Sciences Corp. Announces Agreement with Resilience BioSciences Inc.
April 20, 2026